In patients—especially those aged 65 and older—with obstructive sleep apnea and co-occurring type 2 diabetes mellitus, obesity and other cardiometabolic conditions, we suggest a discussion during the initial clinic visit about both the lifestyle approaches and pharmacologic interventions with glucagon-like peptide-1 receptor agonists as evidence-informed approaches to improve obstructive sleep apnea-related apnea–hypopnea index (AHI), control diabetes without hypoglycemic risks, lower weight, blood pressure and lipids, and reduce subsequent risk of stroke and heart attack [19]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.